Form 8-K - Current report:
SEC Accession No. 0001193125-25-005052
Filing Date
2025-01-13
Accepted
2025-01-13 09:08:24
Documents
15
Period of Report
2025-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d885806d8k.htm   iXBRL 8-K 33852
2 EX-99.1 d885806dex991.htm EX-99.1 50481
6 GRAPHIC g885806g33r93.jpg GRAPHIC 2285
  Complete submission text file 0001193125-25-005052.txt   221774

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apls-20250108.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20250108_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20250108_pre.xml EX-101.PRE 10812
17 EXTRACTED XBRL INSTANCE DOCUMENT d885806d8k_htm.xml XML 3475
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 25525065
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)